ClinicalTrials.gg

Program

LPX-TI641

Its studies are mostly in Arthritis, Rheumatoid · Dermatitis, Atopic · Multiple Sclerosis, led by LAPIX Therapeutics.

Furthest: phase 1, since Apr 28, 20233 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
LAPIX Therapeutics32 open or runningphase 1since Apr 28, 2023Apr 28, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 28, 2023First study: phase 1 study in Autoimmune DiseasesFirst studyNCT05853835 · 72 enrolled · United States, Jordan
  2. Sep 26, 2024Phase 1 study in Arthritis, RheumatoidNCT06628206 · 48 enrolled · United States, Jordan
  3. May 13, 2025Phase 1 study in Dermatitis, AtopicNCT06982352 · 48 planned · United States, Jordan

Ahead

  1. Nov 15, 2026Primary completion: phase 1 study in Arthritis, RheumatoidNCT06628206

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06982352Dermatitis, Atopic · United States, Jordan1RecruitingJan 15, 202648
NCT06628206Arthritis, Rheumatoid · United States, Jordan1Active, not recruitingNov 15, 202648
NCT05853835Autoimmune Diseases · United States, Jordan1CompletedAug 15, 202472

How it is read

Names in the registry

  • “LPX-TI641”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.